Michael B. Bottorff, PharmD: The clinical burden of atrial fibrillation is pretty significant in the United States. I can give you some statistics from the CDC (Centers for Disease Control and Prevention) in Atlanta (and they use a variety of different sources for this, including the American Heart Association): there are about 6 million people in the United States that have atrial fibrillation—that’s 2% or less of the population age 65 and below, but 9% of the population of the age 65 and greater. So, it does represent a disease of, primarily, the elderly population.
There are about 750,000 hospitalizations every year associated with atrial fibrillation, so the cost burden is primarily related to those hospitalizations. That results in approximately 130,000 deaths. And then, if you look at the cost burden, it’s estimated to be over $6 billion a year.
There’s a very strong relationship between atrial fibrillation, particularly nonvalvular atrial fibrillation, and the risk for stroke. There’s Framingham data that’s been around for a long time that projects that if you have atrial fibrillation, compared to similar looking patients who don’t, the risk of stroke is about 5 times higher. Now, for individual patients, it will probably depend what that individual stroke risk is based on a lot of other individual patient characteristics.
The association of stroke in nonvalvular atrial fibrillation, and the importance of anticoagulation in that setting was first studied back in the 1990s with warfarin trials. And compared to not using any anticoagulant at all, those warfarin studies were associated with about a 65% reduction in the risk of stroke. So, it’s a very important component of risk reduction in atrial fibrillation—using an anticoagulant.
It’s difficult, sometimes, to assess how appropriate these agents are when used in patients with atrial fibrillation because, unfortunately, a lot of trials show the patients who should be getting full anticoagulation are actually not receiving it. And some of those estimates are that as many as half of atrial fibrillation patients are not being adequately anticoagulated.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
A Look at Racial Disparities in US HPV Vaccine Uptake
March 1st 2022On this episode of Managed Care Cast, Leslie Cofie, PhD, MPH, an assistant professor of health education and promotion at the College of Health and Human Performance, East Carolina University, discusses his work on identifying and addressing racial disparities in human papillomavirus (HPV) vaccine uptake in the United States.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More